206 related articles for article (PubMed ID: 17441963)
21. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
22. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
23. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides.
Fukushima M; Suzuki N; Emura T; Yano S; Kazuno H; Tada Y; Yamada Y; Asao T
Biochem Pharmacol; 2000 May; 59(10):1227-36. PubMed ID: 10736423
[TBL] [Abstract][Full Text] [Related]
24. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
de Bruin M; van Capel T; Van der Born K; Kruyt FA; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
Br J Cancer; 2003 Mar; 88(6):957-64. PubMed ID: 12644837
[TBL] [Abstract][Full Text] [Related]
25. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Lee JJ; Seraj J; Yoshida K; Mizuguchi H; Strychor S; Fiejdasz J; Faulkner T; Parise RA; Fawcett P; Pollice L; Mason S; Hague J; Croft M; Nugteren J; Tedder C; Sun W; Chu E; Beumer JH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):515-26. PubMed ID: 26787503
[TBL] [Abstract][Full Text] [Related]
26. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.
Yamashita F; Komoto I; Oka H; Kuwata K; Takeuchi M; Nakagawa F; Yoshisue K; Chiba M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):325-33. PubMed ID: 26084259
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
Doi T; Ohtsu A; Yoshino T; Boku N; Onozawa Y; Fukutomi A; Hironaka S; Koizumi W; Sasaki T
Br J Cancer; 2012 Jul; 107(3):429-34. PubMed ID: 22735906
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Tsuchiya H; Kuwata K; Nagayama S; Yamashita K; Kamiya H; Harashima H
Drug Metab Pharmacokinet; 2004 Jun; 19(3):206-15. PubMed ID: 15499188
[TBL] [Abstract][Full Text] [Related]
29. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
30. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells.
Temmink OH; Comijn EM; Fukushima M; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1491-4. PubMed ID: 15571283
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.
Peters GJ
Ther Adv Med Oncol; 2015 Nov; 7(6):340-56. PubMed ID: 26557901
[TBL] [Abstract][Full Text] [Related]
32. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Temmink OH; Hoebe EK; Fukushima M; Peters GJ
Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
[TBL] [Abstract][Full Text] [Related]
33. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
[TBL] [Abstract][Full Text] [Related]
34. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Overman MJ; Varadhachary G; Kopetz S; Thomas MB; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff PM; Xiong H; Abbruzzese JL
Invest New Drugs; 2008 Oct; 26(5):445-54. PubMed ID: 18528634
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Suetsugu T; Mori R; Futamura M; Fukada M; Tanaka H; Yasufuku I; Sato Y; Iwata Y; Imai T; Imai H; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yoshida K
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649846
[TBL] [Abstract][Full Text] [Related]
37. Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Kashiwagi S; Maeda K; Hirakawa K; Ohira M
Anticancer Res; 2020 Jul; 40(7):4157-4163. PubMed ID: 32620665
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
39. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
40. DNA synthesis inhibitors for the treatment of gastrointestinal cancer.
Yasui H; Tsurita G; Imai K
Expert Opin Pharmacother; 2014 Nov; 15(16):2361-72. PubMed ID: 25256052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
